MX9305016A - Metodo para inhibir la replicacion hiv utilizando il-4. - Google Patents

Metodo para inhibir la replicacion hiv utilizando il-4.

Info

Publication number
MX9305016A
MX9305016A MX9305016A MX9305016A MX9305016A MX 9305016 A MX9305016 A MX 9305016A MX 9305016 A MX9305016 A MX 9305016A MX 9305016 A MX9305016 A MX 9305016A MX 9305016 A MX9305016 A MX 9305016A
Authority
MX
Mexico
Prior art keywords
pct
hiv replication
inhibiting hiv
sec
date
Prior art date
Application number
MX9305016A
Other languages
English (en)
Inventor
Jerome Schwarts
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX9305016A publication Critical patent/MX9305016A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

na invención proporciona un método para tratar infección HIV en un paciente, que comprende administrar al paciente infectado con HIV una cantidad terapéuticamente efectiva de IL-4. Esta invención se relaciona con un método para inhibir la replicación HIV en células de monocito/macrófago que emplea interleucina-4.
MX9305016A 1992-08-19 1993-08-18 Metodo para inhibir la replicacion hiv utilizando il-4. MX9305016A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93213492A 1992-08-19 1992-08-19

Publications (1)

Publication Number Publication Date
MX9305016A true MX9305016A (es) 1994-02-28

Family

ID=25461831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305016A MX9305016A (es) 1992-08-19 1993-08-18 Metodo para inhibir la replicacion hiv utilizando il-4.

Country Status (22)

Country Link
US (1) US5700461A (es)
EP (1) EP0656785B1 (es)
JP (1) JP2711182B2 (es)
KR (1) KR950702838A (es)
CN (1) CN1086437A (es)
AT (1) ATE163860T1 (es)
AU (1) AU683427B2 (es)
CA (1) CA2142862C (es)
CZ (1) CZ38095A3 (es)
DE (1) DE69317428T2 (es)
ES (1) ES2113549T3 (es)
FI (1) FI950696A (es)
HU (1) HUT72709A (es)
IL (1) IL106717A0 (es)
MX (1) MX9305016A (es)
NO (1) NO950599L (es)
NZ (1) NZ255735A (es)
PL (1) PL307508A1 (es)
SK (1) SK21295A3 (es)
TW (1) TW291439B (es)
WO (1) WO1994004179A1 (es)
ZA (1) ZA936018B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0858343B1 (en) 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy
US20040132161A1 (en) * 1998-04-20 2004-07-08 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
US20050124645A1 (en) * 1998-04-20 2005-06-09 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
US20030232738A1 (en) * 1998-04-20 2003-12-18 National Jewish Medical And Research Center Method and composition for increasing CD4+ T lymphocyte immune responsiveness
CA2335617C (en) * 1998-06-24 2009-12-15 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
US6734192B1 (en) 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPH02485A (ja) * 1987-08-03 1990-01-05 Yuu Honshiyo 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
CA2078676A1 (en) * 1990-03-21 1991-09-22 Jerome Schwartz Use of il-4 to enhance immune response to infectious antigenic challenges
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
EP0490006B1 (en) * 1990-12-13 1994-06-22 Schering-Plough Pharmaceutical compositions for the treatment of B-cell malignancies

Also Published As

Publication number Publication date
NZ255735A (en) 1997-06-24
KR950702838A (ko) 1995-08-23
ES2113549T3 (es) 1998-05-01
FI950696A0 (fi) 1995-02-16
HUT72709A (en) 1996-05-28
US5700461A (en) 1997-12-23
WO1994004179A1 (en) 1994-03-03
PL307508A1 (en) 1995-05-29
CZ38095A3 (en) 1995-12-13
IL106717A0 (en) 1993-12-08
NO950599D0 (no) 1995-02-17
JPH07506116A (ja) 1995-07-06
AU5007593A (en) 1994-03-15
HU9500487D0 (en) 1995-04-28
EP0656785B1 (en) 1998-03-11
CA2142862A1 (en) 1994-03-03
DE69317428D1 (de) 1998-04-16
EP0656785A1 (en) 1995-06-14
CA2142862C (en) 2000-05-30
ZA936018B (en) 1994-06-13
TW291439B (es) 1996-11-21
SK21295A3 (en) 1997-01-08
CN1086437A (zh) 1994-05-11
FI950696A (fi) 1995-02-16
AU683427B2 (en) 1997-11-13
ATE163860T1 (de) 1998-03-15
JP2711182B2 (ja) 1998-02-10
NO950599L (no) 1995-02-17
DE69317428T2 (de) 1998-07-02

Similar Documents

Publication Publication Date Title
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ES2150022T3 (es) Aerosol farmaceutico que contiene al menos un azucar.
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
ES2098920T3 (es) Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina.
NO2012003I2 (no) 4-aminopyridin
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
AU4923093A (en) Inhibitors of metazoan parasite proteases
BR9509975A (pt) Formulação farmacêutica
MX9305016A (es) Metodo para inhibir la replicacion hiv utilizando il-4.
TW261532B (es)
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
AU1081695A (en) The use of an ester of inositoltrisphosphate for the preparing of medicaments
EE03385B1 (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
DK0651648T3 (da) Farmaceutisk præparat indeholdende IL-6. Anvendelse deraf til behandling af konsumptiv trombo-hæmoragisk sygdom
SE9504267D0 (sv) New therapeutic use
ES2170807T3 (es) Uso de prostaglandinas para la fabricacion de un medicamento para la prevencion y el tratamiento de catarata secundaria.
FI952855A0 (fi) Uudet triatsolokinatsoliinit, niiden valmistus ja käyttö
GB9310049D0 (en) Growth factor effects
ZA983211B (en) Use of mizolastine for preparing medication for the treatment of inflammation
DK0678022T3 (da) Anvendelse af riluzol ved fremstilling af lægemidler, som er anvendelige til behandling af stråleskader